# Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

> **NCT03661307** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 73 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Recurrent Myelodysplastic Syndrome
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Quizartinib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03661307
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-10-31
- **Primary completion:** 2028-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 73 (ESTIMATED)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03661307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03661307, "Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03661307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*